Bifogade filer
SenzaGen secures orders of SEK 1.3 million from a US-based world-leading chemical company
Prenumeration
Beskrivning
| Land | Sverige |
|---|---|
| Lista | First North Stockholm |
| Sektor | Hälsovård |
| Industri | Bioteknik |
SenzaGen has received new assignments from an existing customer in the chemicals industry with a total order value of approximately SEK 1.3 million. The assignments were secured at the end of the third quarter and will be carried out at SenzaGen’s GLP-certified laboratories in Lund and Milan, as well as through a partner laboratory. The testing includes the company’s proprietary non-animal method GARD®skin for skin sensitization, along with complementary methods for other regulatory toxicology endpoints.
Substances in the chemicals industry are often both challenging to assess and potentially hazardous. Reliable and accurate test results are therefore crucial to ensure they do not cause harm to humans – an area where SenzaGen has solid experience and broad expertise.
“We support some of the world’s largest chemicals companies in ensuring the safety of their substances. Customers choose us because our advanced test methods make it possible to evaluate even the most challenging chemicals. This order confirms that the SenzaGen Group has a unique and competitive offering that meets the high demands of our customers”, says Peter Nählstedt, President and CEO of SenzaGen.
The GARD® technology is based on genomics and machine learning and generates highly reliable and accurate decision support for both pure chemicals and more complex substances and mixtures that have traditionally been difficult to test. The test is approved for regulatory use by the OECD in accordance with TG 497 and TG 442E.